Earnings Call Transcript - LFST Q4 2023

Operator, Operator

Good morning. My name is Audra and I will be your conference operator today. I would like to welcome everyone to the LifeStance Health Fourth Quarter 2023 Earnings Call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. I would like to turn the conference over to Monica Prokocki, Vice President of Investor Relations.

Monica Prokocki, Vice President of Investor Relations

Thank you, operator. Good morning, everyone, and welcome to LifeStance Health's fourth quarter 2023 earnings conference call. I'm Monica Prokocki, Vice President of Investor Relations. Joining me today are Ken Burdick, Chief Executive Officer; Dave Bourdon, Chief Financial Officer; and Danish Qureshi, Chief Operating Officer. We issued the earnings release and presentation before the market opened this morning. Both are available on the Investor Relations section of our website, investor.lifestance.com. In addition, a replay of this conference call will be available following the call. Before turning the call over to management for their prepared remarks, please direct your attention to the disclaimers about forward-looking statements included in the earnings press release and SEC filings. Today's remarks contain forward-looking statements, including statements about our financial performance outlook, business model, and strategy. Those statements involve risks, uncertainties, and other factors, as noted in our periodic filings with the SEC that could cause actual results to differ materially. In addition, please note that we report results using non-GAAP financial measures, which we believe provide additional information for investors to help facilitate comparison of current and past performance. A reconciliation to the most directly comparable GAAP measures is included in the earnings press release tables and presentation appendix. Unless otherwise noted, all results are compared to the comparable period in the prior year. At this time, I'll turn the call over to Ken Burdick, CEO of LifeStance. Ken?

Ken Burdick, CEO

Thanks, Monica, and thank you all for joining us today. I'd like to begin by highlighting what we stand for here at LifeStance. Every day we are focused on three foundational pillars: the patient experience, clinical quality, and developing an inclusive, purpose-driven culture. First, we are committed to putting the patient experience at the forefront of everything we do. Since the start of the pandemic, the country has experienced an alarming increase in the rates of anxiety and depression as well as deaths resulting from overdose and suicide. More than 150 million people live in an area with a shortage of mental health professionals, and only 56% of psychiatrists accept commercial insurance. Tens of millions of Americans are unable to access mental health care treatment, with devastating effects on families and communities. In 2023, LifeStance's team of over 6600 clinicians helped address these access challenges by providing mental health services to over 880,000 patients who depend on our care. With our differentiated hybrid model of in-person and virtual visits, we meet patients where they are. By accepting insurance, we provide patients with affordable access to mental health care, whereas much of the market is cash pay and therefore out of reach for the majority of Americans. The exceptional care provided by our clinicians is reflected in the feedback we receive from our patients. In 2023, LifeStance received a patient net promoter score of 82, and our average Google review score across all LifeStance centers stood at 4.5 out of five stars. As you will hear in our prepared remarks, we continue to focus on enhancing the end-to-end experience for our patients. Second, we're dedicated to clinical quality. LifeStance and our team of multi-disciplinary clinicians are committed to providing patients with personalized, high-quality care with clinical integrity. We provide training programs for our clinicians and conduct clinical audits to conform with best practice guidelines, which also afford an opportunity for our clinical leaders to collaborate with and mentor our clinicians. Our focus is on delivering the most appropriate treatment for each patient's individual needs based on informed clinical judgment. As we enhance our capabilities around clinical quality, I am excited to announce the appointment of Dr. Ujjwal Ramtekkar as Chief Medical Officer. He joined LifeStance in January and is off to a great start. Ujjwal is board certified in pediatric and adult psychiatry and has held multiple senior clinical leadership roles in our industry. Last but not least, we are evolving from an entrepreneurial company focused almost exclusively on growth to one that is more balanced and disciplined when it comes to prioritization and execution. While we continue to grow as a company, we are also growing up to ensure that as a company, we have the people, systems, processes, and culture to deliver on our mission at scale. As a leadership team, we are committed to developing a sustainable, inclusive, and purpose-driven culture that keeps our organization aligned with our vision, mission, and values. 2024 represents the second year of our two-year plan to invest in the business, fortify our foundation, and standardize our operations. At the one-year mark, we're beginning to see some tangible benefits. First, we beat on all guided metrics for the full year 2023. This quarter represents the fifth consecutive quarter that LifeStance has met or exceeded expectations across all financial metrics. Second, we are making solid progress on our three strategic investments. We remain on track to launch both our human resource information system and our new credentialing and clinician onboarding system by this summer. For the third initiative, the electronic health record, we completed the initial discovery process where we identified incremental opportunities for improvement with our existing platform. For 2024, we are focused on those improvements and enhancing related processes. As a result, we will further evaluate our long-term EHR solution in 2025. One example of the improvements we are making is a digital patient check-in tool that we believe will enhance the patient, clinician, and front office staff experience while reducing our administrative costs. While it is still early, we have seen encouraging results in our initial launch. Furthermore, we have become much more strategic when it comes to our payer strategy. In 2023, we terminated roughly 30% of our 440 payer contracts. In 2024, we will continue to evaluate our payer relationships and focus on aligning with payer partners who share our vision of expanding access to mental healthcare. Lastly, we continue to remain laser-focused on profitability while making the near-term investments needed for the long-term success of the business. This was the first time in recent quarters where our revenue grew faster than our adjusted general and administrative expenses. Going forward, we expect operating leverage and margin expansion to be the norm at LifeStance. This year, we will continue to strengthen our operational processes by streamlining, standardizing, and automating end-to-end workflows. While we have made meaningful progress, there is plenty of work remaining to improve our operational and financial performance. In other words, we have steadied the ship, but we have not yet come close to optimizing the potential of our business. With that, I'll turn it over to Dave to provide additional commentary on our fourth quarter and full year financial performance, as well as our 2024 guidance. Dave?

Dave Bourdon, CFO

Thanks, Ken. Like Ken, I'm pleased with the team's operational and financial performance in 2023, exceeding our expectations for the full year. In the fourth quarter, we achieved strong top-line results with revenue of $281 million, representing growth of 22% year over year, with outperformance in the quarter driven primarily by positive visit volumes as our clinicians delivered more visits during the holiday season than expected. Visit volumes of 1.8 million increased 20% year over year, primarily driven by organic clinician growth and modest productivity improvements. Total revenue per visit increased by 2% year over year to $157, primarily driven by payer rate increases. For the full year, we delivered revenue of $1.56 billion, up 23% year over year. Regarding profitability, the better-than-expected top-line results flowed through to center margin. Center margin of $83 million in the quarter increased by 33% year over year. Full-year center margin of $302 million grew 27% year over year. Adjusted EBITDA of $20 million in the quarter was strong and consistent with our expectations. Our fourth quarter adjusted EBITDA increased 99% year over year. For the full year, adjusted EBITDA was $59 million, representing 5.6% of revenue. Turning to liquidity, in the fourth quarter, we generated positive free cash flow of $5 million and $17 million in cash from operating activities. These improvements in cash flow were driven by higher collections with days sales outstanding improvement of eleven days from 52 in Q3 to 41 in Q4. Each one of these days represents approximately $3 million in cash. As expected, DSO improved in Q4 as we released claims that we had intentionally held in Q3 due to positive updates from rate negotiations with several large payers. Free cash flow and cash from operating activities were negatively impacted in the quarter due to the shareholder litigation settlement. As disclosed in an 8-K filing earlier this month, we have now fulfilled our obligations related to this settlement, which we discussed in our last earnings call. This included intentionally accelerating into Q4 the final $25 million payment that was due in Q1. For the full year 2023, free cash flow was negative $57 million, which includes shareholder litigation expenses of approximately $50 million. We exited the quarter with $79 million in cash and net long-term debt of $280 million. We have additional debt capacity from a delayed draw term loan of $8 million as well as a $50 million revolving debt facility providing us with sufficient financial flexibility. In terms of our outlook for 2024, we expect full-year revenue of $1.190 billion to $1.240 billion, center margin of $345 million to $365 million, and adjusted EBITDA of $80 million to $90 million. Our annual guidance assumes year-over-year revenue growth driven primarily by higher visits from clinician growth, combined with a low single-digit increase in the total revenue per visit. Otherwise, we're assuming generally consistent operational performance year over year. Our guidance also contemplates a revenue split of roughly 50/50 in the first and second half of the year due to seasonality. Regarding earnings, as compared to 2023 where they were weighted to the second half, we expect this year's earnings to be more balanced throughout the year. This is due to the timing of investments and variation in rates, which are the result of payer rate changes and other mixed components like geography and services. For the first quarter, we expect revenue of $287 million to $307 million, center margin of $81 million to $93 million, and adjusted EBITDA of $17 million to $23 million. Additionally, we expect stock-based compensation of approximately $80 million to $95 million in 2024, including approximately $20 million to $25 million from new 2024 grants. Consistent with our prior messaging on pausing mergers and acquisitions, we are not planning to pursue any acquisitions in 2024. I'm excited to announce that we expect to achieve a company milestone by generating positive free cash flow for full year 2024. This will be driven by improved profitability and lower capital expenditures as we continue to strategically moderate the opening of de novo centers. We expect leverage to come down significantly this year and anticipate net leverage to be below 2.5 times by the end of the year. We continue to have sufficient financial capacity to run the business and we do not intend to raise additional debt or equity in 2024. Relating to strategic initiatives, in 2023, we recognized a total of approximately $5.5 million of cost for the HRIS in credentialing and onboarding platform. Of this, $3 million were recognized as G&A expenses, with the remainder in CapEx. As Ken stated for the EHR, we are focused on improving our existing platform and related processes in 2024 and therefore will not incur any costs in the current year. In closing, we are pleased with the progress we made in 2023 and we are confident as we look ahead to 2024.

Danish Qureshi, COO

Thanks, Dave. We continued to align our teams around two growth priorities: net clinician adds and clinician productivity. We grew by 227 net clinician ads in the fourth quarter and 1014 for the full year, bringing our total clinicians to 6645, an increase of 18% year over year. Importantly, our growth in Q4 remains 100% organic for the third consecutive quarter. Our clinician value proposition remains strong, and we are proud of our clinician recruiting and operations teams' great work in delivering clinician growth in 2023. Turning to clinician productivity, for 2023 on a visits per average clinician basis, we saw productivity increase by 2%, driven by many of the operational actions we took throughout the year. As a reminder, productivity is a function of two components, clinician capacity or the time clinicians give us, and utilization, our ability to fill clinician time with patients. In 2023, we put our focus on utilization, delivering on our core commitment to our clinicians to fill their schedules by driving operational discipline throughout the patient funnel. At the top of the funnel, we made enhancements to our primary care referral team, organic search traffic, internal clinician referrals, and enterprise referral partnerships. These actions delivered improvements in attracting new patients above the growth of our clinician base demonstrated by our growing waitlist for services. I will note that our cost per new patient acquisition continued to decline year over year, and we spend a minimal amount on paid advertising as part of our top-of-funnel strategy. Second, at the middle of the funnel in terms of converting patients to scheduled appointments, we continued to leverage our digital capabilities to improve patient matching via our online booking experience, which we rolled out nationwide. Additionally, we enhanced the patient experience with better online clinician profiles, reduced scheduling complexity, and improvements to our phone intake processes, which is a key area for 2024. Finally, at the bottom of the funnel in terms of scheduled appointments converting to completed visits, our cancellation and no-show rates have now stabilized in the 9% to 10% range, which is a significant improvement from the previous 15% level when we set this as the focus area for improvement. As we head into 2024, we are shifting our attention to the other side of the productivity equation, clinician capacity. We have early initiatives in place to grow overall clinician capacity, with a goal to reward and incentivize those clinicians offering full-time hours. For example, we are using tiered benefits to provide incentives such as medical coverage and 401k match to full-time clinicians. Additionally, our recruiting team is focused on attracting clinicians who desire full-time employment, and finally, we offer equity ownership through our long-term incentive program to attract and retain our highest contributing clinicians. In addition to improving clinician productivity, we made notable strides in other areas during the past year. First, in terms of leadership, we reorganized and upgraded our practice operations senior leadership team. We made significant changes by streamlining the number of senior leaders, promoting top performers, and bringing in new external talent with the appropriate skill set to guide an organization of LifeStance's current and future scale. Second, in terms of KPIs, we reoriented our operations teams around a metrics-driven approach to managing the business and instituted a new reporting suite of KPIs to bring focus, prioritization, and data-driven decision-making to the organization while continuing to emphasize the patient and clinician experience. Third, in terms of culture, we recentered the company around supporting local operations and clinician needs while emphasizing belonging and connection. For example, we prioritized increased teammate engagement via social gatherings, recognition and appreciation, and participation in community volunteer events. Fourth, in terms of cost efficiency, we completed our real estate optimization project. In total, we consolidated 82 centers in 2023 with little to no disruption to our patients and clinicians. We opened 35 de novo centers and will continue to intentionally moderate our pace of openings with an expectation of no more than 20 de novos in 2024. Finally, we made tangible progress in standardizing and streamlining the business, including moving to a single EHR phone system, KPI suite, and online booking tool, as well as creating a single operating model for our regional support teams. Looking ahead to 2024, there is no shortage of opportunities for improvement with many new initiatives unlocked by the work done in 2023. Delivering an amazing patient and clinician experience remains a top priority for us. I'd like to take a moment to discuss three tangible examples of how we are going to do this while also generating operating leverage. First, we are continuing to invest in the front office of our centers, focusing our resources on those areas of support that most directly impact the experience of our patients and clinicians. We are increasing our center staffing levels over 25% by year-end and redesigning our processes to better support our patients, clinicians, and administrative support teams. Second, we are making improvements for new patients booking by phone. We are rolling out a new phone booking tool that leverages the matching capabilities of our online booking tool. This will further enhance the patient-matching experience while significantly reducing complexity and increasing the speed of scheduling over the phone for our intake team. Third, we are piloting a new digital patient check-in tool that will allow us to collect and verify patient information upfront as well as allow patients to pay their balances more easily. This will reduce stress for our patients and manual complexity for our operations and billing teams. We are doing all three of these things while also meeting our commitments to margin expansion in 2024, demonstrating that delivering improved patient and clinician experiences while also delivering improved operating leverage can be accomplished simultaneously. I'm proud of what our teams have accomplished over the past year and am equally excited about the opportunities in front of us in 2024 and beyond. I'm also particularly proud of the strength of the leadership bench that we have built, which delivered on our commitments for the full year 2023 and will be instrumental in leading the long-term profitable growth of the business. With that, I'll turn it back to Ken for his closing remarks.

Ken Burdick, CEO

Thanks, Danish. In closing, I am encouraged by the progress made in 2023. We remain focused on operational improvements, profitable growth, and disciplined capital deployment. Our 2024 guidance reflects the strong positive momentum of the organization, and we look forward to continuing to invest in the patient and clinician experience while at the same time delivering margin expansion. In particular, I am thrilled that we expect to achieve the important milestone of positive free cash flow for 2024. Along with Dave and Danish, I offer my thanks and appreciation to our 9500 colleagues who demonstrate their dedication to our vision, mission, and values in the work they do every day. It is due to their collective efforts that we have made significant strides toward realizing LifeStance's potential. Operator, please open up the line for Q&A.

Operator, Operator

Thank you. We'll go first to Craig Hettenbach at Morgan Stanley.

Craig Hettenbach, Analyst

Great. Thank you. Ken, despite the comments of an improved track record that you've seen in the last five quarters, there's still some noise out there in terms of clinician turnover and growth. So I'd love to get your take in terms of things you've done to kind of steady the ship and expectations going forward on those metrics.

Ken Burdick, CEO

Sure. I'm going to let Danish respond to the clinician turnover. Generally, what I would say is obviously, we posted a strong fourth quarter. And as Danish, Dave, and I have all said in our prepared remarks, there's plenty of work that remains to be done. And I'll let Danish perhaps elaborate on some of his comments as it relates to clinician growth and retention.

Danish Qureshi, COO

Sure. Hey Craig, so in terms of clinician retention, it continues to remain stable. We have wins throughout 2023 and feel really good about what we've been able to accomplish there. But as I indicated in my prepared remarks, we are continuing to focus on enhancing our value proposition to our clinicians through the way that we are investing in the practice group, things like I mentioned around increasing our front office staffing to have a very tangible and direct feeling of support for our clinicians across the country as one specific example. But as indicated by our net clinician adds of over 1,000, which we're very proud of, our ability to both attract and retain clinicians remains strong. We continue to be able to do that despite moving to what has essentially been for the last three quarters, 100% organic and delivered net clinician adds above 2022 while moving towards a 100% organic strategy. So all in all, we feel great about where we're at today.

Craig Hettenbach, Analyst

Got it. And then just a follow-up question for Dave, just on operating leverage. I know whether it's footprint consolidation, payer consolidation, there's a number of things at play. But this year in particular, are there any that you would single out in terms of what's going to be important for you to deliver upgrade leverage, and then maybe as you go into 2025, does that look the same or different things that come into the fold?

Dave Bourdon, CFO

Craig, it's Dave. I think I got the gist of your question, which was focused on operating leverage. You were cutting out pretty bad. As far as the operating leverage, yes, we're guiding to improvements in operating leverage in 2024. One of the ways we're doing that is if you look at our Q1 guide and our full year guide on general and administrative expenses, it's pretty flat throughout the year. The way I explain that is, in the first quarter, you're going to get a pop-up in G&A as a result of the resumption of the payroll taxes. And then as that goes away in the subsequent quarters, it's being replaced by some of the investments that Danish talked about, such as the digital check-in tool and other initiatives. But having said that, we're able to keep G&A spend relatively flat because of the efficiencies that we've been working on as we've been strengthening and fortifying the business. So we feel really good about the margin expansion that we're seeing both in the bottom line as well as incentive margin for 2024.

Craig Hettenbach, Analyst

Good. Thanks for that.

Lisa Gill, Analyst

Thanks very much and good morning. Ken, I was wondering if you could give us an update on where you are in the managed care payer check-in strategy. How much is left to be done here in 2024? And then when I look at the revenue per clinician, I think you talked about rates getting better in the fourth quarter and holding some claims until the fourth quarter. How do I think about that progression of revenue per clinician going into 2024?

Ken Burdick, CEO

Sure. Lisa, I'll take the first part of that and let Danish speak to the revenue per clinician. Our payer strategy really is going to continue the work that we started in 2023, which I was very surprised to see the number of payer contracts we had. It was well in excess of 400. We reduced that by about 30% last year. We will do an additional reduction this year, probably not quite as large. But I think what's most important is sharing the underlying rationale of why we're doing it. So when we think about our payer contracts, first and foremost, we found that we had many where there was such little volume. It just didn't make sense administratively to maintain the work, to reload the rates, to do the credentialing, et cetera. So that's important. Beyond volume, we look at the administrative terms that we have with the payer and try to make them simple and straightforward and not overly complex and onerous. We also look at whether or not we have delegated credentialing because we have found there's a dramatic reduction in the time it takes to onboard a clinician when they grant us delegation. Lastly, we consider reimbursement that we're paid and their desire and willingness to partner with us with strategic initiatives such as value-based care and integrated care between physical and mental health.

Dave Bourdon, CFO

Lisa, this is Dave. I'll address your question about total revenue per visit growth. In the fourth quarter, we experienced a significant increase in the revenue per clinician. The key factors contributing to the rise in total revenue per visit during this period were the higher-margin services we've discussed, such as neuropsych testing. Additionally, we saw some favorable increases in payer rates in the fourth quarter, which were primarily adjustments for 2024 that came in a bit earlier than expected. This contributed to the overall increase in total revenue per visit for the fourth quarter. Regarding the issues with claims, that was mainly a cash-related situation, which affected our cash flow, but we were still recognizing revenue at appropriate levels, so it did not impact our total revenue per visit. It mostly affected our days sales outstanding. As you mentioned, we released those claims, and you observed a significant decrease in days sales outstanding in the fourth quarter as anticipated.

Lisa Gill, Analyst

And if I can just squeeze in a quick follow-up. Just you talked about full-time employees and the capacity opportunity there. Can you talk about how many of your clinicians are full-time today and what the ultimate goal would be?

Danish Qureshi, COO

Yes, this is Danish. So our long-term goal is to always make sure that we're creating an environment where clinicians feel like they can dedicate their full caseload and time to LifeStance, and we continue to enhance our benefits to create incentives and rewards for clinicians to do that. However, we do have both clinicians that are providing what you would consider full-time hours, and we have ones that are more part-time. Our value proposition, though different for each, continues to resonate for both. The point in our prepared remarks was that we continue to focus our energies around incentivizing and rewarding clinicians to really build their careers here and have this be their primary or only source of income.

Dylan Finley, Analyst

Thank you very much. This is actually Dylan Finley on for Kevin Caliendo. As you guys are approaching '25 and your prior comments on exiting that year with double-digit margins, I guess, first of all, that's still a reasonable objective as of today? And then secondly, based on the improvement indicated in '24, it seems like '25 might be a year with a little more of a heavier lift. I'm just wondering if you could break out the sources of that margin expansion. Does that contemplate further center margin improvement versus a reduction in certain operating expenses?

Ken Burdick, CEO

Yes, as we look at the guidance for '24 and our previous comments relative to exiting '25 at double-digit margins, I would describe this as right on track. We've said in the past it wouldn't necessarily be completely linear. We're really pleased that compared to our sort of long-term comments where we were projecting and committing to free cash flow for full year 2025, in this call this morning, we're announcing that a year early, such that in 2024, we are now expecting a full year that we will generate free cash.

Brian Tanquilut, Analyst

Hey, good morning, guys. Maybe just to Danish's point on increasing incentive offers to clinicians, how should we be thinking about the impact of that on salaries, wages, and benefits as you roll that out?

Danish Qureshi, COO

This would be a new benefits program. This is just reshaping the overall benefits program that we administer to help lean heavier towards incentivizing clinicians that are offering full-time hours versus those that remain part-time or very part-time. So there's not a growth in the overall cost structure regarding benefits, just again a shaping of how we are aligning that between part-time and full-time clinicians.

Ken Burdick, CEO

Yes, certainly, on a macro basis, the demand for outpatient mental health services has not subsided at all. So we have a very significant long-term tailwind there. Specifically to LifeStance, obviously as we continue to grow larger and larger, the days of 75% and 100% year-over-year growth are behind us. We continue to feel strong conviction around our estimates of mid-teen organic growth, and then obviously, when we return to pursuing acquisitions, that will drive it beyond the mid-teens. We think there's plenty of opportunity for continued growth in the business even as we focus on margin expansion and profitability and efficient capital deployment.

Stephanie Davis, Analyst

Hey guys, congrats on the quarter and thanks for taking my question. First, Danish, we've seen some rapidly changing trends over the past few years around patient acquisition, efficiency, and cost. I was hoping we could dig in a little more into that patient acquisition strategy you touched on your comments. Talk to me about top of funnel versus middle funnel versus bottom of the funnel and kind of how much mind share each is taking and maybe what areas you could be focusing less on versus some of the prior years?

Danish Qureshi, COO

Sure, Stephanie, thanks for the question. As I mentioned in our prepared remarks, we continue to focus on all three top, middle, and bottom of the funnel. However, as I reflect on 2023, a considerable amount of our effort went into improvements in the bottom of the funnel, which we have discussed each quarter regarding the improvements we saw in our no-show and cancellation rates, which dropped approximately five to six points over the year. Although there remains some additional opportunity in that space over time, I view the work in optimizing the bottom of the funnel as complete and stable. Consequently, we will continue to shift our attention toward particularly the middle of the funnel, where we are improving our matching capabilities, both online and through our phone intake process by utilizing many of the capabilities developed first for online booking. Furthermore, the top of the funnel will always be a focus. We have demonstrated not just patient acquisition in terms of volume above the growth of our clinician base, but we have also managed to deliver that while lowering the cost of acquisition for each new visit. However, patient demand will continue to outstrip supply. Therefore, while top-of-funnel focus will remain essential, middle-of-the-funnel improvements will be our primary focus for 2024.

Ken Burdick, CEO

I'll add that I think one of the most powerful things that Danish has shared in his remarks is the extent to which we are able to rely on referrals from physicians, such that our paid advertising to acquire new patients is quite minimal, frankly, compared to some others in our space.

Operator, Operator

And there are no further questions at this time. I would like to turn the conference over to Ken Burdick for closing remarks.

Ken Burdick, CEO

Thank you. As I've shared previously, the founders of LifeStance designed a great model to achieve exceptional growth and have given newcomers like myself and Dave an opportunity to evolve and scale a great business. I want to remind everyone, we are still in the early stages. We are a young business. We have grown through both acquisition, approximately 100 acquired independent practices, and thousands of clinicians hired one by one. As we continue to emphasize these phrases like operational improvement and plenty of work to do, I want you to understand that is not vacuous; that is a realistic acknowledgment of where we are in our multiyear journey. We have more work to do. We continue to improve our focus on execution, prioritization, and standardization so that we can run a more efficient business. Recognizing that there's more work to do, I do want to be sure to call out that I could not be more proud of my teammates across LifeStance. The passion that they demonstrate, the work ethic that they display has not only been key to our past accomplishments, but it's going to be the source of our future achievements as we continue to realize the potential of our business. Thank you for your interest in LifeStance, and thanks for joining us today.

Operator, Operator

And this does conclude today's conference call. Thank you for your participation. You may now disconnect.